Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer
The purpose of this study is to identify a dose of SB-485232 which is safe, tolerable and biologically active when used in combination with pegylated liposomal doxorubicin (Doxil) in patients with epithelial ovarian cancer. This study will use a standard treatment regimen of pegylated liposomal doxorubicin (Doxil) in combination with rising doses of SB-485232. The dose selected from this study will be used in a future studies to evaluate the efficacy of this combination.
Neoplasms, Ovarian
DRUG: SB-485232 (interleukin 18), pegylated liposomal doxorubicin
Safety and tolerability of SB-485232/Doxil combination therapy, 16 weeks
Biological activity of SB-485232/Doxil combination therapy, 16 weeks|Pharmacokinetic parameters for SB-485232 and Doxil: AUC(0-t), Cmax, and Cmin, 16 weeks|Pharmacodynamic biomarker responses, 16 weeks|Immunogenicity (anti-SB-485232 and anti-PEG antibodies), 16 weeks|Anti-tumor activity (Radiographic tumor assessments and serum CA-125 levels), 16 weeks
The purpose of this study is to identify a dose of SB-485232 which is safe, tolerable and biologically active when used in combination with pegylated liposomal doxorubicin (Doxil) in patients with epithelial ovarian cancer. This study will use a standard treatment regimen of pegylated liposomal doxorubicin (Doxil) in combination with rising doses of SB-485232. The dose selected from this study will be used in a future studies to evaluate the efficacy of this combination.